Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 14/20 | 0.49 |
| ▸ | TACR1 | P25103 | 12/20 | 0.49 |
| ▸ | TACR3 | P29371 | 8/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678434 | 0.91 | TACR2 (0.47) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8349876 | 0.83 | TACR2 (0.46) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8593224 | 0.80 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL8347396 | 0.79 | TACR2 (0.48) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6448730 | 0.79 | TACR2 (0.47) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6951866 | 0.79 | TACR2 (0.62) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8296076 | 0.78 | TACR2 (0.44) | TACR2TACR1CCR5 | |
| SCHEMBL7088993 | 0.77 | TACR2 (0.65) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL5677576 | 0.77 | TACR2 (0.65) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8566728 | 0.77 | TACR2 (0.49) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5770735-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-23 | — | — | US | claimed |
| US-7041679-B2 | Crystalline forms of osanetant | SANOFI-AVENTIS (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20040044215-A1 | Crystalline forms of osanetant | SANOFI-AVENTIS (FR) | 2004-03-04 | — | — | US | disclosed |
| EP-1102747-B1 | CRYSTALLINE FORMS OF OSANETANT | SANOFI SYNTHELABO (FR) | 2003-06-18 | — | — | EP | disclosed |
| EP-0512901-B1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-06-23 | — | — | EP | disclosed |
| US-5770735-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-23 | — | — | US | disclosed |
| US-5625060-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present | Sanofi, Elf (FR) | 1997-04-29 | — | — | US | disclosed |
| US-5340822-A | Substance P, neurokinin antagonists | ELF SANOFI (FR) | 1994-08-23 | — | — | US | disclosed |
| EP-0512901-A1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-11 | — | — | EP | disclosed |